Edwards Lifesciences (EW) Soars 4.34% on Strong Q1 Earnings

Edwards Lifesciences (EW) shares rose 0.17% today, marking the fourth consecutive day of gains, with a total increase of 4.34% over the past four days. The stock price reached its highest level since July 2024, with an intraday gain of 0.68%.

The strategy of buying EW shares after they reached a recent high and holding for 1 week yielded moderate returns over the past 5 years. The annualized return was 18.62%, which outperformed the market by 3.66%. However, this was slightly lower than the average annual return of 26.51% achieved by Live Nation Entertainment over the same period. This suggests that while the strategy showed decent performance, it may not have fully capitalized on broader market opportunities.

Edwards Lifesciences' stock price has been on an upward trajectory, driven by several key factors. The company's strong Q1 2025 financial results, released on April 23, 2025, played a significant role in boosting investor confidence. The company reported impressive sales of $1.4 billion, which exceeded market expectations and highlighted the company's robust performance in the medical device sector.

Additionally, Morgan Stanley's recent decision to raise its price target for Edwards Lifesciences shares from $70.00 to $75.00 has further fueled investor optimism. This move by the financial institution reflects a positive outlook on the company's future prospects and has likely contributed to the recent surge in stock price. The increased price target suggests that analysts believe Edwards Lifesciences is well-positioned to continue its growth trajectory, making it an attractive investment option for many.